- Open Access
The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
© Bouchal et al; licensee BioMed Central Ltd. 2011
- Received: 25 May 2011
- Accepted: 31 October 2011
- Published: 31 October 2011
The initial pharmacokinetic study of a new anticancer agent (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12) was complemented by proteomic screening of rat plasma. The objective of the study was to identify new LA-12 target proteins that serve as markers of LA-12 treatment, response and therapy monitoring.
Proteomic profiles were measured by surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) in 72 samples of rat plasma randomized according to LA-12 dose and time from administration. Correlation of 92 peak clusters with platinum concentration was evaluated using Spearman correlation analysis.
We identified Retinol-binding protein 4 (RBP4) whose level correlated with LA-12 level in treated rats. Similar results were observed in randomly selected patients involved in Phase I clinical trials.
RBP4 induction is in agreement with known RBP4 regulation by amantadine and cisplatin. Since retinol metabolism is disrupted in many cancers and inversely associates with malignancy, these data identify a potential novel mechanism for the action of LA-12 and other similar anti-cancer drugs.
- (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12)
- plasma retinol-binding protein 4
The platinum-based anti-cancer drug, cisplatin (cis-diamminedichloroplatinum(II)), is commonly used for treatment of various types of carcinomas, including breast, testicular, ovarian, head and neck or lung cancer , with significant anti-tumor activity. However, its clinical use is substantially complicated by numerous side effects such as nephrotoxicity, neurotoxicity and nausea as well as by intrinsic or acquired resistances. Significant efforts were therefore dedicated to develop novel platinum-based complexes to reduce the side effects of cisplatin, to overcome platinum resistance and to introduce novel mechanisms of anti-cancer action. Two derivatives, carboplatin (cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II)) and oxaliplatin (trans-[R, R-cyclohexane-1,2-diammine]oxalatoplatinum(II)), have been approved by the Food and Drug Administration for clinical use [2, 3]. The requirement for their intravenous administration, in addition to substantial side effects, led to the development of a new generation of platinum-based drugs such as satraplatin ((OC-6-43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV)), known also as JM216, the first orally administered platinum compound evaluated in clinical trials [2, 4, 5]. We studied the biological properties of an alternative platinum(IV) complex called LA-12, (OC-6-43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV), containing 1-adamantylamine instead of cyclohexylamine non-leaving ligand  which provides different chemical and biological properties and which has also entered into clinical evaluation. LA-12 has shown a higher cytotoxicity than satraplatin when tested on a panel of 14 cancer cell lines of various origins and different cisplatin sensitivities [6, 7] and no cross-resistance with cisplatin [6, 8]. LA-12 has also shown higher anti-tumor activity in comparison with cisplatin and satraplatin, favorable pharmacokinetics and relatively low acute toxicity in a panel of pre-clinical in vivo studies [9–11]. Generally, the cytotoxic mode of cisplatin action is mediated by its interaction with DNA to form DNA adducts, primarily intra-strand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73 and MAPK, and culminate in the induction of apoptosis . The mechanisms of LA-12 action are not fully understood. There is evidence that exposure to LA-12 can disrupt cell proliferation and induce apoptosis more potently than cisplatin in both p53 dependent and independent manners [13, 14]. In particular, LA-12 induces unique changes in the profile of gene expression compared to cisplatin, indicating a distinct mode of action resulting in the differential activation of both p53-dependent and p53-independent gene targets . Most recently, LA-12 has been shown to have a greater inhibitory effect than cisplatin on heat shock protein 90 function .
To understand the molecular mechanisms of LA-12 action and identify serum markers for LA-12 activity in cancer patients, we performed dose-response and time-course studies using mass-spectrometry-based analysis to measure the proteomic profiles of rat plasma in response to LA-12 and compared them with the recent pharmacokinetic data . Such an experimental design enables identification of LA-12 target proteins which could potentially serve as markers of LA-12 treatment, response and therapy monitoring. Using the surface-enhanced laser desorption-ionization time-of-flight mass spectrometry (SELDI-TOF MS) approach  we identified Retinol-binding protein 4 (RBP4) as significantly correlating with LA-12 level in both rat plasma and rat plasma ultrafiltrate and in the plasma of patients undergoing LA-12 treatment in Phase I clinical trials. In view of the known roles of retinol in controlling cellular differentiation and the abnormal expression of RBP4 in cancer , these data contribute to understanding LA-12 action as an anti-cancer agent and identify RBP4 as a serum marker for LA-12 activity.
Chemicals, animals and dosing
LA-12 was synthesized by Pliva-Lachema. 36 male albino Wistar-Hahn rats (6-8 weeks of age, 235-268 g) were kept under 12-h light/dark cycle with free access to water and standard diet for 13 days for acclimatization prior to experiments. All animal protocols were approved by the Institute's Animal Experimental Ethics Committee and animals were treated according to OECD guidelines. In the morning after overnight fasting, LA-12 was administered by a gastric gavage in a volume of 1 mL/kg of body weight as suspension in a 0.6% water solution of methylcellulose. Rats were randomly assigned to four LA-12 dosing groups of 9 rats dosed with 37.5 - 75 - 150 - and 300 mg LA-12/kg body weight each and, furthermore, to two of six blood sampling intervals (pre-dose and at 2, 8, 24, 48 and 72 h after dosage). Each combination of dosage and blood sampling time was thus represented by three animals. Two blood samples of 2 mL each were taken (at different times after dosage) from retro-orbital plexus under ether anesthesia. Blood was collected into polypropylene test tubes containing 0.75% K3EDTA (20 μL/mL of blood) and cooled in water bath (8°C) for 5 min. The samples were then centrifuged at 3000 g and 8°C for 10 min. The first aliquot (0.1 mL) of the supernatant was immediately frozen at -18°C while plasma ultrafiltrate was prepared from the remaining blood volume (see  for protocol) and stored at -18°C. After the second blood sampling interval, rats were killed by withdrawing whole blood from the abdominal artery.
SELDI-TOF MS analysis
20 μL of rat plasma were denatured with 30 μL of sample solution (9 M urea, 2% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)) for 30 min at room temperature (RT). Denatured plasma proteins were centrifuged (10,000 ×g/20 min/RT), the supernatant was mixed with 90 μL of IMAC binding buffer (Bio-Rad, USA) and loaded on IMAC-Cu SELDI chips according to manufacturer's instructions. After matrix (sinapinic acid) application, sample protein composition was analyzed using SELDI-TOF MS in PBS IIc Protein Chip Reader (Bio-Rad, USA) as described previously [18, 20]. All samples characterized by one of four LA-12 doses and one of six time intervals, each obtained by three independent blood collections from individual animals (biological replicates) were measured twice; 4*6*3*2 = 144 averaged MS spectra were thus obtained. Peak clustering was performed with Biomarker Wizard software (Bio-Rad, USA) with signal/noise (S/N) > 5 and 5% minimum spectra detection in the first pass and then peaks with S/N > 3 in cluster mass window of range 0.3% were added; the valley depth was set to three fold of noise. Intensities of corresponding peaks across all six replicates (three biological replicates, each measured twice) were then averaged before quantitative statistical analysis.
Platinum concentration measurement
Platinum concentration in both rat plasma and ultrafiltrate samples as well as in human plasma samples were determined by a validated method based on electrothermal atomic absorption analysis with Zeeman background correction, as described previously . An AAnalyst 800 spectrometer (Perkin Elmer, Norwalk, CT, USA) with longitudinal AC-Zeeman-effect background correction with transversely heated graphite tube (THGA™) and autosampler AS 800 were used .
The primary SELDI-TOF MS data consisting of six replicates (three biological replicates, each measured twice) were inspected for outliers and aggregated using average prior further statistical analyses. Values under detection limit were taken as half of this limit. Standard nonparametric descriptive statistics were adopted, i.e. median and percentile range.
The platinum concentrations in response to LA-12 dose and time since drug administration were statistically evaluated using Kruskal-Wallis test. The average intensities of all 92 protein peak clusters across the whole SELDI-TOF MS experiment were correlated with platinum concentration in corresponding samples using Spearman rank correlation coefficient. All analyses were performed using Statistica 9 software (StatSoft, Inc., USA).
For identification of proteins that correlate with plasma platinum level, rat plasma samples containing highest levels of the proteins of interest were pre-separated using four IMAC Spin Columns (Bio-Rad, USA) (1 mg of total protein for each column) according to the manufacturer's instructions, with 2 × 100 μL of 250 mM imidazole in binding buffer as the elution buffer. Eluted protein mixtures were dialyzed overnight against 40 mM Tris-HCl buffer (pH 7.0), combined and dried under vacuum. The pellet of IMAC pre-separated proteins was resolubilized in 80 μL of sample solution containing 10% acetonitrile and 0.1% trifluoroacetic acid for further reverse phase-liquid chromatography fractionation. This fractionation was performed on an Agilent HP 1100 HPLC system (Agilent Technologies, Santa Clara, CA, USA) using a Discovery Bio Wide Pore C18 column (10 cm × 2.1 mm, 5 μm particle size; Sigma-Aldrich Corp., St. Louis, MO, USA) with a 2 cm guard precolumn. Separations were performed at 35°C, mobile phase A consisted of 0.1% trifluoroacetic acid in water while mobile phase B consisted of 0.1% trifluoroacetic acid in acetonitrile. The proteins were eluted using a linear gradient of mobile phase B (0% to 91% B in 15 min, then 91% B to 96% B in 18 min, then 96% B to 100% B in 2 min) followed by elution using 100% mobile phase B in 10 min; the flow rate was 100 μL/min (following the method of Moshkovskii et al. , with several modifications). Sixty collected fractions (60 μL each) were dried under vacuum and resolubilized in 20 μL 10% acetonitrile and 0.1% trifluoroacetic acid for protein profile determination on SELDI-TOF MS (2 μL of each resolubilized fraction was analyzed on NP-20 chips). The proteins were redissolved in 20 μL of sample buffer (consisting of 12% SDS, 6% mercaptoethanol, 30% glycerol, 0.05% Coomassie Brilliant Blue G-250 and 150 mM Tris-HCl, pH 7.0), heated (95°C/3 min), centrifuged (16,000 × g/20 min/4°C) and separated using tricine SDS-PAGE on PROTEAN II XL apparatus (Bio-Rad, USA) according to Schägger . The gel - consisting of 4% sample loading gel, 10% spacer gel and 16% separation gel - was stained using colloidal Commassie Blue . The bands with appropriate molecular weight were cut out and digested by trypsin as described previously . Mass spectra were recorded in positive reflectron mode on a 4800 MALDI TOF/TOF™ mass spectrometer (Applied Biosystems, Framingham, MA, USA) equipped with an Nd:YAG laser (335 nm) using 3-7 ns pulse and with 200-Hz firing rate. Delayed extraction was used in all experiments being optimized for m/z = 2100 in MS mode. The maximum pulse energy was 23 μJ, it was attenuated appropriately for sample analysis. Accelerating voltage of the ion source was set to 20 kV in the MS mode. In the MS/MS mode, the accelerating voltage was 8 kV; it was modified after ion selection so the ions passing the collision cell possessed 1 keV of kinetic energy; the accelerating voltage rose to 15 kV after ions passed the collision cell. Dual microchannel plate detector voltage was set to 1.86 kV in MS mode and 2.10 kV in MS/MS mode. MS spectra were acquired in the mass range of 800-4000 m/z and calibrated internally using the monoisotopic [M+H]+ ions of trypsin autoproteolytic fragments (842.509 Da and 2211.104 Da). Peak detection was performed using the internal algorithm of the 4000 Series Explorer™ Software (version 3.6; Applied Biosystems) with signal-to-noise ratio (S/N) higher than 55 in MS mode and S/N > 20 in MS/MS mode using cluster area optimization feature. Up to 5 precursors from MS spectra with S/N > 100 were automatically selected for MS/MS fragmentation analysis using the interpretation method of the Explorer™ Software. MS/MS acquisition of precursors was controlled according to decreasing S/N value. The isolation parameter for precursor selection was set to 200 as for the resolution of ion gating mechanism.
The mgf peak lists were generated from mass spectra using the Peaks-to-Mascot function incorporated in the Explorer™ software. From MS analysis, peaks in the m/z range of 800-4000 and with S/N > 30 were included in the mgf peak list. From MS/MS analysis, peaks fulfilling two following criteria were included in the mgf peak lists: (i) S/N > 15 and (ii) the m/z range between 68 and the value of 50 m/z units lower than precursor's m/z value. The peak lists containing both MS and MS/MS data were submitted through Mascot Daemon (ver. 2.1.0) to Mascot Server (local installation of database search engine, ver. 2.1.04). Parameters for combined search (MS and MS/MS data) were as follows: database - UniProt SwissProt (release 2011_01); taxonomy - all entries; enzyme - trypsin; allowed missed cleavages - 1; fixed modifications - carbamidomethyl (C); variable modifications - oxidation (M), pyro-cmC (N-term camC), pyro-glu (N-term E), pyro-glu (N- term Q); peptide tolerance - 30 ppm; MS/MS tolerance - 250 mmu; peptide charge - (+1); monoisotopic masses; instrument - MALDI-TOF-PSD; no restrictions on protein molecular weight and pI value were applied. The hits passing the following criteria were concluded as a successful protein identification: (i) protein score C.I. = 100%, (ii) total ion score C.I. = 100%, and (iii) and at least two successfully fragmented peptides with ion score C.I = 100% each.
Determination of RBP4 level in plasma of patients from LA-12 clinical evaluation
Patients with solid tumors undergoing Phase I clinical trials were administered orally by LA-12. Blood was collected into test-tubes containing 40 μL of 3.75% K3EDTA before administration and 0.5-1-2-4-8 h after administration, centrifuged at 4000 rpm at 4°C for 10 min. The plasma was transferred into labeled polypropylene test-tubes and immediately frozen and stored in a freezer (-18°C). Plasma samples from patients containing 30 μg of total protein were separated by SDS-PAGE and transferred onto nitrocellulose membranes which were incubated with primary antibody (Anti-RBP4, Sigma-Aldrich, USA, cat. No. HPA001641), detected with peroxidase conjugated anti-rabbit IgG (Dako, UK) and ECL detection reagents (GE Healthcare, Sweden). Band intensities were quantified using QuantityOne 4.6.1 software (Bio-Rad, USA).
Rat RBP4 protein identification data
Plasma retinol-binding protein precursor (RBP4)
Protein Score C.I. %
Total Ion Score
Total Ion Score C.I. %
Sequence Coverage %
3.3 × 10-42
R.QRQEELCLER.Q + Pyro-glu (N-term Q)
RBP4 is a plasma protein characterized by Kanai and Goodman  as a transport protein for retinol produced in hepatocytes to extrahepatic tissues. Retinoids (retinol, all-trans retinoic acid and related signaling molecules) are involved in cellular differentiation pathways and induce differentiation of various types of stem cells . Components of the retinol pathway are disrupted in cancer, which suggests that a reduction of retinoid signaling is involved in tumor development. This applies to RBP4 and RBP1, amongst others, which are down-regulated by methylation in cancer . Also, RBP4 is known to influence the differentiation of adipocytes  and to mediate insulin resistance through its functional relationship to glucose transporter 4 .
In principle, the RBP4 correlation with LA-12 observed in our data might be caused by two major reasons: (i) by formation of a RBP4/LA-12 complex analogous to that of RBP4/retinol, or (ii) by induction of RBP4 protein expression. In order to explore the first hypothesis, we performed a molecular modeling of the RBP4/LA-12 complex to investigate whether LA-12 is able to bind non-covalently into the retinol binding site in the RBP4 structure. In such a case, RBP4 would hypothetically serve as a LA-12 transport protein analogously to the retinol. The modeling revealed that the central cavity of the protein is too small for binding of LA-12 and the protein would have to undertake a significant conformational change to form a cavity capable of binding LA-12. The comparative analysis of the apo and holo structures of RBP4  revealed some flexibility in the loop composed of residues 34-37 (Additional file 7). However, the other side of the binding cavity is made of a rigid β-barrel, making significant enlargement of the cavity unlikely. The above observations are supported by the fact that no peak with 553 Da mass shift (corresponding to LA-12 molecular weight) was detected in the surroundings of peak No. 75 in SELDI-TOF MS spectra (Additional file 2). It is thus unlikely that a hypothetical RBP4/LA-12 complex plays a significant role in LA-12 and/or RBP4 function.
On the other hand, the second hypothesis of direct or indirect induction of RBP4 expression by LA-12 is supported by induction of RBP4 by amantadine, a drug bearing an adamantine group closely related to that present in LA-12 . Additional indirect evidence was indicated by Hung et al. who reported increased level of urinary RBP4 in mice after cisplatin treatment . This suggests similar mechanisms for RBP4 induction by both LA-12 and cisplatin. The time dependence of the RBP4 level in rat plasma also corresponds well with the protein stability which has been estimated for approximately 30 h .
Functionally, RBP4 is aberrantly expressed in a number of human cancers, with promoter hypermethylation leading to down-regulation of expression in esophageal squamous cancer . Most recently, Lorkova et al.  reported a decreased level of RBP4 in sera of ovarian cancer patients using two-dimensional gel electrophoresis and confirmed this observation via western blotting and ELISA. In view of the roles of retinol in cellular differentiation, the lack of RBP4 expression is thought to be involved in maintaining the undifferentiated nature of cancer cells . Thus, in addition to acting as a marker, elevated RBP4 levels following treatment with LA-12 may have functional importance through the restoration of retinol-induced signaling pathways in cancer cells. As such, these data open very interesting, much more complex and not yet investigated hypothesis on RBP4 involvement in cancer development and the mechanisms of action of LA-12 and similar anti-cancer drugs.
Using mass spectrometry-based proteomics, we identified induction of RBP4 by the new anticancer agent LA-12 in both rat and human plasma. RBP4 is a plasma protein involved in the transport of retinol, which serves as a differentiation-inducing molecule in various stem cells and is aberrantly expressed in cancer.
The authors' team is based at Masaryk Memorial Cancer Institute, Brno, Czech Republic and at cooperating institutes (Masaryk University, University of Defence and Platinum Pharmaceuticals). The interdisciplinary team consists of specialists in cancer proteomics (PB-proteomics group leader; IS, KH, MM), biostatistics (JJ), proteomics mass spectrometry (LH), molecular modeling and protein engineering (JD), tumor biology and immunochemistry (BV) as well as of LA-12 project leader (PS). BV is a scientific director of Regional Centre of Applied Molecular Oncology (RECAMO, http://www.recamo.cz).
We would like to thank Dr. Philip J. Coates for critical reading of the manuscript. This work was supported by the Czech Science Foundation (project No. P304/10/0868), by Czech Ministry of Health (projects No. NS/9812-4 and MZ0MOU2005), by Czech Ministry of Education (project No. MSM0021622413) and by European Regional Development Fund and the State Budget of the Czech Republic (RECAMO; CZ.1.05/2.1.00/03.0101).
- Ho YP, Au-Yeung SC, To KK: Platinum-based anticancer agents: innovative design strategies and biological perspectives. Medicinal Research Reviews 2003, 23: 633–655. 10.1002/med.10038PubMedView ArticleGoogle Scholar
- Kozubik A, Vaculova A, Soucek K, Vondracek J, Turanek J, Hofmanova J: Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism. Metal-Based Drugs 2008, 2008: 417897.PubMed CentralPubMedView ArticleGoogle Scholar
- Choy H, Park C, Yao M: Current status and future prospects for satraplatin, an oral platinum analogue. Clinical Cancer Research 2008, 14: 1633–1638. 10.1158/1078-0432.CCR-07-2176PubMedView ArticleGoogle Scholar
- Fokkema E, Groen HJ, Bauer J, Uges DR, Weil C, Smith IE: Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. Journal of Clinical Oncology 1999, 17: 3822–3827.PubMedGoogle Scholar
- Kelland LR: An update on satraplatin: the first orally available platinum anticancer drug. Expert Opinion on Investigational Drugs 2000, 9: 1373–1382. 10.1517/13543722.214.171.1243PubMedView ArticleGoogle Scholar
- Zak F, Turanek J, Kroutil A, Sova P, Mistr A, Poulova A, Mikolin P, Zak Z, Kasna A, Zaluska D, et al.: Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines. Journal of Medicinal Chemistry 2004, 47: 761–763. 10.1021/jm030858+PubMedView ArticleGoogle Scholar
- Turanek J, Kasna A, Zaluska D, Neca J, Kvardova V, Knotigova P, Horvath V, L SI, Kozubik A, Sova P, et al.: New platinum(IV) complex with adamantylamine ligand as a promising anti-cancer drug: comparison of in vitro cytotoxic potential towards A2780/cisR cisplatin-resistant cell line within homologous series of platinum(IV) complexes. Anti-Cancer Drugs 2004, 15: 537–543. 10.1097/01.cad.0000127147.57796.e5PubMedView ArticleGoogle Scholar
- Horvath V, Blanarova O, Svihalkova-Sindlerova L, Soucek K, Hofmanova J, Sova P, Kroutil A, Fedorocko P, Kozubik A: Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells. Gynecologic Oncology 2006, 102: 32–40. 10.1016/j.ygyno.2005.11.016PubMedView ArticleGoogle Scholar
- Cermanova J, Chladek J, Soval P, Kroutil A, Semerad M, Berankova Z, Siroky P, Surova I: Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6–43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs. Methods and Findings in Experimental and Clinical Pharmacology 2004, 26: 679–685. 10.1358/mf.2004.26.9.872565PubMedView ArticleGoogle Scholar
- Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M: Preclinical anti-tumor activity of a new oral platinum(IV) drug LA-12. Anti-Cancer Drugs 2005, 16: 653–657. 10.1097/00001813-200507000-00010PubMedView ArticleGoogle Scholar
- Sova P, Mistr A, Kroutil A, Zak F, Pouckova P, Zadinova M: Comparative anti-tumor efficacy of two orally administered platinum(IV) drugs in nude mice bearing human tumor xenografts. Anti-Cancer Drugs 2006, 17: 201–206. 10.1097/00001813-200602000-00012PubMedView ArticleGoogle Scholar
- Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22: 7265–7279. 10.1038/sj.onc.1206933PubMedView ArticleGoogle Scholar
- Horvath V, Soucek K, Svihalkova-Sindlerova L, Vondracek J, Blanarova O, Hofmanova J, Sova P, Kozubik A: Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin. Investigational New Drugs 2007, 25: 435–443. 10.1007/s10637-007-9062-7PubMedView ArticleGoogle Scholar
- Roubalova E, Kvardova V, Hrstka R, Borilova S, Michalova E, Dubska L, Muller P, Sova P, Vojtesek B: The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Investigational New Drugs 2010, 28: 445–453. 10.1007/s10637-009-9270-4PubMedView ArticleGoogle Scholar
- Hrstka R, Powell DJ, Kvardova V, Roubalova E, Bourougaa K, Candeias MM, Sova P, Zak F, Fahraeus R, Vojtesek B: The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anti-Cancer Drugs 2008, 19: 369–379. 10.1097/CAD.0b013e3282f7f500PubMedView ArticleGoogle Scholar
- Kvardova V, Hrstka R, Walerych D, Muller P, Matoulkova E, Hruskova V, Stelclova D, Sova P, Vojtesek B: The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Molecular Cancer 2010, 9: 147. 10.1186/1476-4598-9-147PubMed CentralPubMedView ArticleGoogle Scholar
- Sova P, Mistr A, Kroutil A, Semerad M, Chlubnova H, Hruskova V, Chladkova J, Chladek J: A comparative study of pharmacokinetics, urinary excretion and tissue distribution of platinum in rats following a single-dose oral administration of two platinum(IV) complexes LA-12 (OC-6–43)-bis(acetato)(1-adamantylamine)amminedichloroplatinum(IV) and satraplatin (OC-6–43)-bis(acetato)amminedichloro(cyclohexylamine)platinum(IV). Cancer Chemotherapy and Pharmacology 2011, 67: 1247–1256. 10.1007/s00280-010-1411-0PubMedView ArticleGoogle Scholar
- Pilny R, Bouchal P, Borilova S, Ceskova P, Zaloudik J, Vyzula R, Vojtesek B, Valik D: Surface-enhanced laser desorption ionization/time-of-flight mass spectrometry reveals significant artifacts in serum obtained from clot activator-containing collection devices. Clinical Chemistry 2006, 52: 2115–2116. 10.1373/clinchem.2006.073841PubMedView ArticleGoogle Scholar
- Tang XH, Gudas LJ: Retinoids, retinoic acid receptors, and cancer. Annual Review of Pathology 2011, 6: 345–364. 10.1146/annurev-pathol-011110-130303PubMedView ArticleGoogle Scholar
- Brozkova K, Budinska E, Bouchal P, Hernychova L, Knoflickova D, Valik D, Vyzula R, Vojtesek B, Nenutil R: Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Research 2008, 10: R48.PubMed CentralPubMedView ArticleGoogle Scholar
- Moshkovskii SA, Serebryakova MV, Kuteykin-Teplyakov KB, Tikhonova OV, Goufman EI, Zgoda VG, Taranets IN, Makarov OV, Archakov AI: Ovarian cancer marker of 11.7 kDa detected by proteomics is a serum amyloid A1. Proteomics 2005, 5: 3790–3797. 10.1002/pmic.200401205PubMedView ArticleGoogle Scholar
- Schagger H: Tricine-SDS-PAGE. Nature Protocols 2006, 1: 16–22. 10.1038/nprot.2006.4PubMedView ArticleGoogle Scholar
- Matsui NM, Smith-Beckerman DM, Epstein LB: Staining of Preparative 2-D Gels. In 2-D Proteome Analysis Protocols. Volume 112. Edited by: L AJ. Totowa, New Yersey: Humana Press; 1999:307–311.View ArticleGoogle Scholar
- Havlasova J, Hernychova L, Brychta M, Hubalek M, Lenco J, Larsson P, Lundqvist M, Forsman M, Krocova Z, Stulik J, Macela A: Proteomic analysis of anti-Francisella tularensis LVS antibody response in murine model of tularemia. Proteomics 2005, 5: 2090–2103. 10.1002/pmic.200401123PubMedView ArticleGoogle Scholar
- Kanai M, Raz A, Goodman DS: Retinol-binding protein: the transport protein for vitamin A in human plasma. Journal of Clinical Investigation 1968, 47: 2025–2044. 10.1172/JCI105889PubMed CentralPubMedView ArticleGoogle Scholar
- Tsunoda S, Smith E, De Young NJ, Wang X, Tian ZQ, Liu JF, Jamieson GG, Drew PA: Methylation of CLDN6, FBN2, RBP1, RBP4, TFPI2, and TMEFF2 in esophageal squamous cell carcinoma. Oncology Reports 2009, 21: 1067–1073.PubMedView ArticleGoogle Scholar
- Zovich DC, Orologa A, Okuno M, Kong LW, Talmage DA, Piantedosi R, Goodman DS, Blaner WS: Differentiation-dependent expression of retinoid-binding proteins in BFC-1 beta adipocytes. Journal of Biological Chemistry 1992, 267: 13884–13889.PubMedGoogle Scholar
- Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436: 356–362. 10.1038/nature03711PubMedView ArticleGoogle Scholar
- Zanotti G, Ottonello S, Berni R, Monaco HL: Crystal-Structure of the Trigonal Form of Human Plasma Retinol-Binding Protein at 2.5-Angstrom Resolution. Journal of Molecular Biology 1993, 230: 613–624. 10.1006/jmbi.1993.1173PubMedView ArticleGoogle Scholar
- Cross-Reference To Related Source [http://www.freepatentsonline.com/y2008/0033053.html]
- Hung YC, Huang GS, Lin LW, Hong MY, Se PS: Thea sinensis melanin prevents cisplatin-induced nephrotoxicity in mice. Food and Chemical Toxicology 2007, 45: 1123–1130. 10.1016/j.fct.2006.12.017PubMedView ArticleGoogle Scholar
- ExPASy [http://www.expasy.org/cgi-bin/protparam1?P04916@noft@]
- Lorkova L, Pospisilova J, Lacheta J, Leahomschi S, Zivny J, Cibula D, Petrak J: Decreased concentrations of retinol-binding protein 4 in sera of epithelial ovarian cancer patients: A potential biomarker identified by proteomics. Oncology Reports, in press.Google Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.